FDA Aims Neglected Tropical Disease Guidance At Inexperienced Sponsors
This article was originally published in PharmAsia News
Executive Summary
Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.
You may also be interested in...
FDA Adds Three “Qualifying Pathogens” For Potential Antibiotic Incentives
Final rule includes a total of 21 pathogens, but agency notes a drug intended to treat a pathogen on the list is not guaranteed a QIDP designation for priority review and potential added marketing exclusivity.
FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.